Movement disorders refer to a group of neurological conditions that impair a person’s ability to move or control their movements. They are usually caused by interference in the brain’s coordination of muscle activity and may involve too much movement or too little movement. Typically, affected individuals experience uncontrollable, often repetitive, movements or decreased ability to move. Common examples of movement disorders include Parkinson’s disease, Huntington’s disease, dystonia, essential tremor, and Tourette’s syndrome. Parkinson’s disease is the most common type of movement disorder, affecting approximately 1 million Americans. It is characterized by tremor, stiffness of the limbs, slowness of movement, and difficulty in walking, leading to problems with balance and coordination. Another common movement disorder is Huntington’s disease, an inherited disorder that causes progressive, involuntary jerking movements. Tourette’s syndrome is a neuropsychiatric disorder characterized by repetitive motor tics and vocal tics. The symptoms of Tourette’s syndrome can include rapid and consistent eye blinking, shoulder shrugging, and facial grimacing. Dystonia is a motor disorder that causes twisting, repetitive movements or abnormal postures. Essential tremor occurs when an individual experiences uncontrollable shakes or tremors in their hands, arms, legs, or head, often worsened by activities like writing or eating. Movement disorders are typically diagnosed after a physical exam and review of medical history. Further testing, such as genetic testing, neurological imaging, and blood tests may be utilized to confirm diagnosis and rule out other conditions. Treatments vary depending on the type and severity of the movement disorder. Commonly used treatments include medications, physical therapy, and/or surgical procedures. In conclusion, movement disorders are a group of neurological conditions that impair a person’s ability to move or control their movements.
Title : Novel important cellular responses, signaling mechanisms and therapeutic options in vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : TBI updates in 2025
Jonathan Eskenazi, Cedars Sinai / UCLA, United States
Title : A case of vile vindictive primary CNS vasculitis
George Diaz, Memorial Healthcare Systems, United States
Title : Non-pharmacological strategies to counteract oxaliplatin toxicity: Protective effects of vagal nerve stimulation and resistance training on neuropathy, motor dysfunction, and muscle atrophy
Ricardo Aparecido Baptista Nucci, Hospital Sirio-Libanes, Brazil
Title : Synapticare: Integrating sleep data and tau biomarkers to assess depression severity
Medha Menon, John Foster Dulles HS, United States
Title : How have we eliminated infection: From the bone to brain?
Thomas J Webster, Interstellar Therapeutics, United States